Drug Profile

Pegipanermin - INmune Bio

Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XPro^TM

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emory University; Xencor
Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Phase II Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
Preclinical HER2 positive breast cancer
No development reported Neurodegenerative disorders; Non-alcoholic steatohepatitis; Solid tumours
Discontinued COVID-19 respiratory infection; Parkinson's disease

01 Jul 2025 Efficacy and adverse events data from a phase II MINDFuL trial in Alzheimer's disease released by INmune Bio
10 Jun 2025 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by INmune Bio
08 May 2025 INmune Bio plans a phase II trial for Major depressive disorder (Treatment-resistant) once NIH funding is available

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com